Transcription networks rewire gene repertoire to coordinate cellular reprograming in prostate cancer.
Chromatin remodeling
Epithelial-mesenchymal transition
Lineage plasticity
Pioneer factors
Therapy resistance
Journal
Seminars in cancer biology
ISSN: 1096-3650
Titre abrégé: Semin Cancer Biol
Pays: England
ID NLM: 9010218
Informations de publication
Date de publication:
02 2023
02 2023
Historique:
received:
03
10
2022
revised:
04
01
2023
accepted:
18
01
2023
pubmed:
27
1
2023
medline:
15
2
2023
entrez:
26
1
2023
Statut:
ppublish
Résumé
Transcription factors (TFs) represent the most commonly deregulated DNA-binding class of proteins associated with multiple human cancers. They can act as transcriptional activators or repressors that rewire the cistrome, resulting in cellular reprogramming during cancer progression. Deregulation of TFs is associated with the onset and maintenance of various cancer types including prostate cancer. An emerging subset of TFs has been implicated in the regulation of multiple cancer hallmarks during tumorigenesis. Here, we discuss the role of key TFs which modulate transcriptional cicuitries involved in the development and progression of prostate cancer. We further highlight the role of TFs associated with key cancer hallmarks, including, chromatin remodeling, genome instability, DNA repair, invasion, and metastasis. We also discuss the pluripotent function of TFs in conferring lineage plasticity, that aids in disease progression to neuroendocrine prostate cancer. At the end, we summarize the current understanding and approaches employed for the therapeutic targeting of TFs and their cofactors in the clinical setups to prevent disease progression.
Identifiants
pubmed: 36702449
pii: S1044-579X(23)00004-4
doi: 10.1016/j.semcancer.2023.01.004
pii:
doi:
Substances chimiques
Transcription Factors
0
Chromatin
0
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
76-91Informations de copyright
Copyright © 2023 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Conflict of interest The authors declare no conflicts of interest.